Capricor Therapeutics, Inc.

About Capricor Therapeutics, Inc.

Capricor Therapeutics is a late-stage biotechnology company developing cell and exosome-based therapeutics for Duchenne muscular dystrophy and other rare diseases. Its lead asset, CAP-1002, is an allogeneic cardiosphere-derived cell therapy in Phase 3 trials. The company also advances exosome vaccine candidates and exosome-mediated delivery platforms for RNA, proteins and gene therapies.